Prospective Head-To-Head Comparative Phase 3 Study Between 18F-Fluciclovine and 68Ga-PSMA-11 PET/CT in Patients with Early BCR.

[tango65]

This study concluded with several take-home messages:

Due to higher lesion-to-background ratio, 68Ga-PSMA-11 PET/CT demonstrates superior detection rates and reader agreement than 18F-fluciclovine PET/CT

The primary and secondary endpoints were met: 68Ga-PSMA-11 PET/CT detection rates per patients, for pelvic lymph node regions, and for extra-pelvic metastasis were more than twice as high for those for 18F-fluciclovine PET/CT

PSMA should be the PET agent of choice when PET/CT imaging is considered for subsequent treatment management decisions in patients with prostate cancer and post-radical prostatectomy biochemical recurrence at low PSA levels and should become the standard of care in these patients

Whether early detection of biochemical recurrence sites by PET/CT imaging affects patient outcomes is the subject of ongoing phase 3 trials

urotoday.com/conference-hig...

[NPfisherman]

If I ever do a scan again--(likely)--I will do the PSMA scan....my PSA was near 3 and I did the Axumin scan ....it found solid uptake on a tumor on my clavicle, but no where else...some tracer left in my one vein on the side where it was infused--not unusual.... the research on the scans makes me believe that I could still have some disease in the prostate bed, ribs, etc... I wish they had the PSMA scan available in 2018, but glad for everyone that it is soon to be available for all.... Thanks for posting, tango65....

Fish

[tango65 in reply to NPfisherman]

I agree. I will follow my cancer with Ga 68 PSMA PET/CT. I had one last January and it was negative (PSA=0.43). We'll repeate when PSA is around 1.

[Hawk56]

Sad that our FDA has yet to approve it. It’s widespread use elsewhere and the data from the various CTs here should make this an “approve now...!”

[tango65 in reply to Hawk56]

It seems that UCLA and UCSF iare asking the FDA for approval for BCR.